Algert Global LLC Boosts Stake in Replimune Group, Inc. (NASDAQ:REPL)

Algert Global LLC raised its position in Replimune Group, Inc. (NASDAQ:REPL) by 5.4% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 84,033 shares of the company’s stock after purchasing an additional 4,340 shares during the quarter. Algert Global LLC owned 0.12% of Replimune Group worth $756,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Acadian Asset Management LLC purchased a new stake in Replimune Group during the 1st quarter worth $927,000. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Replimune Group in the first quarter valued at about $1,088,000. Rafferty Asset Management LLC raised its holdings in shares of Replimune Group by 148.1% during the 4th quarter. Rafferty Asset Management LLC now owns 463,397 shares of the company’s stock valued at $3,906,000 after buying an additional 276,596 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Replimune Group by 12.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after buying an additional 699,679 shares during the period. Finally, Millennium Management LLC lifted its position in Replimune Group by 575.1% during the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after acquiring an additional 2,656,173 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the transaction, the chief financial officer now owns 101,057 shares in the company, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 20.60% of the stock is currently owned by insiders.

Replimune Group Stock Down 1.1 %

Shares of NASDAQ:REPL opened at $11.56 on Friday. The firm has a market cap of $789.78 million, a PE ratio of -3.57 and a beta of 1.21. The company has a fifty day simple moving average of $10.48 and a 200 day simple moving average of $8.62. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group, Inc. has a 12-month low of $4.92 and a 12-month high of $16.70.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Thursday, August 8th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.10. On average, equities research analysts anticipate that Replimune Group, Inc. will post -3.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on REPL. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price target on shares of Replimune Group in a research note on Monday, September 16th. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Finally, Roth Mkm started coverage on Replimune Group in a research note on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price for the company. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $16.80.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.